IndiTreat ® test effectiveness

IndiTreat^® – The potential to predict tumor resistance and sensitivity

Until today, there have been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first-line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance*, causing a measurable burden on clinic resources and immeasurable patient suffering.

Over the last decade, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality. IndiTreat serves you and your clinic with functional information on tumor resistance and sensitivity.

* European Journal of Cancer 81 (2017) 191–202

What does this mean to oncologists and their patients?

The potential to predict tumor resistance and sensitivity to cancer drugs

The power to select the most appropriate treatment, in accordance with guidelines or off-label

The promise to improve patient quality of life through in vitro testing of drug efficacy on the individual patient